1 |
OBERNDORFER F , MULLAUER L . Molecular pathology of lung cancer:current status and perspectives [J]. Curr Opin Oncol,2018,30(2):69-76.
|
2 |
WU J , LIN Z . Non-Small Cell Lung Cancer Targeted Therapy: Drugs and Mechanisms of Drug Resistance[J]. Int J Mol Sci. 2022, 23(23):15056.
|
3 |
ZHENG J , DOU Y , HUANG D , et al . Overall signature of acquired KRAS gene changes in advanced non-small cell lung cancer patient with EGFR-TKI resistance[J]. Jpn J Clin Oncol, 2023,hyad123.
|
4 |
中华医学会病理学分会,国家病理质控中心,中华医学会肿瘤学分会肺癌学组,等 . 非小细胞肺癌MET临床检测中国专家共识[J]. 中华病理学杂志, 2022,51(11):1094-1103.
|
5 |
中国抗癌协会肿瘤病理专业委员会分子病理协作组,中华医学会病理学分会分子病理学组,国家病理质控中心 . 中国非小细胞肺癌RET基因融合临床检测专家共识[J]. 中华病理学杂志,2021,50(6):583-591.
|
6 |
中华医学会肿瘤学分会,中华医学会杂志社 . 中华医学会肺癌临床诊疗指南(2023版)[J]. 中华肿瘤杂志,2023,45(7):539-574.
|
7 |
ETTINGER D S , WOOD D E , AISNER D L , et al . Non-Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology[J]. J Natl Compr Canc Netw, 2022,20(5):497-530.
|
8 |
苏国苗,王娟,李振辉,等 . 云南地区非小细胞肺癌10种驱动基因突变联合检测分析[J]. 分子诊断与治疗杂志, 2022,14(8):1292-1295+1299.
|
9 |
冯征,文苗苗,王雪娇,等 . 中国西北地区非小细胞肺癌EGFR、ALK、ROS1基因突变和临床病理特征分析[J]. 临床肿瘤学杂志, 2021,26(1):29-33.
|
10 |
陈琳,郭华,孙亚丽,等 . 非小细胞肺癌表皮生长因子受体和ALK基因检测及其与临床病理特征的相关性[J]. 实用医学杂志, 2019,35(11):1739-1743.
|
11 |
邓庆,罗韬,葛佳,等 . 非小细胞肺癌中九基因联合检测突变分析[J]. 临床与实验病理学杂志, 2020,36(6):666-670.
|
12 |
何燕,麻文菁,李进辉,等 . 非小细胞肺癌患者表皮生长因子受体和PIK3CA基因突变与临床病理特征和预后的关系[J]. 中华实用诊断与治疗杂志, 2021,35(6):576-579.
|
13 |
LIN Q , ZHANG H , DING H , et al . The association between BRAF mutation class and clinical features in BRAF-mutant Chinese non-small cell lung cancer patients [J]. J Transl Med, 2019,17(1): 298.
|
14 |
PERRONE F , MAZZASCHI G , MINARI R , et al . Multicenter Observational Study on Metastatic Non-Small Cell Lung Cancer Harboring BRAF Mutations: Focus on Clinical Characteristics and Treatment Outcome of V600E and Non-V600E Subgroups[J]. Cancers (Basel), 2022,14(8): 2019.
|
15 |
HUANG C , ZOU Q , LIU H ,et al . Management of non-small cell lung cancer patients with MET exon 14 skipping mutations[J]. Curr Treat Options Oncol, 2020,21(4): 33.
|
16 |
GAINOR J F , VARGHESE A M , OU S H , et al . ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer[J]. Clin Cancer Res, 2013,19(15): 4273-4281.
|
17 |
CAO J , GU J J , LIANG Y , et al . Evaluate the Prognosis of MYC/TP53 Comutation in Chinese Patients with EGFR-Positive Advanced NSCLC Using Next-Generation Sequencing: A Retrospective Study[J]. Technol Cancer Res Treat, 2022, 21:15330338221138213.
|
18 |
LEE K C , KOH J, CHUNG D H , et al . A case of concomitant EGFR/ALK alteration against a mutated EGFR background in early-stage lung adenocarcinoma[J]. J Pathol Transl Med, 2021,55(2):139-144.
|
19 |
LI D , JIANG H , JIN F , et al . Concurrent classic driver oncogenes mutation with ROS1 rearrangement predicts superior clinical outcome in NSCLC patients[J]. Genes Genomics, 2023,45(1):93-102.
|
20 |
ZHUANG X , ZHAO C , LI J , et al . Clinical features and therapeutic options in non-small cell lung cancer patients with concomitant mutations of EGFR, ALK, ROS1, KRAS or BRAF [J]. Cancer Med, 2019,8(6): 2858-2866.
|
21 |
HUANG M H , LEE J H , HUNG P S , et al . Potential Therapeutic Strategy for EGFR-Mutant Lung Cancer With Concomitant EML4-ALK Rearrangement-Combination of EGFR Tyrosine Kinase Inhibitors and ALK Inhibitors[J]. JTO Clin Res Rep, 2022,3(11):100405.
|
22 |
赵冉,伍潇怡,陈颖玮,等 . 二代测序技术检测650例非小细胞肺癌驱动基因突变[J]. 临床与实验病理学杂志, 2022,38(2):152-156.
|
23 |
中华医学会病理学分会,国家病理质控中心,中华医学会肿瘤学分会肺癌学组 等 . 非小细胞肺癌分子病理检测临床实践指南(2021版)[J]. 中华病理学杂志,2021,50(4):323-332.
|
24 |
鲁涛,李强,李岚,等 . 132例晚期非小细胞肺癌胸腔积液EGFR基因突变检测结果及其临床意义:一项来自单中心的回顾性研究 [J]. 中国肺癌杂志, 2020,23(12):1059-1065.
|
25 |
孙岚,毕阔,刘伟,等 . 非小细胞肺癌患者驱动基因突变及临床病理特征分析[J]. 临床和实验医学杂志, 2022,21(19):2028-2032.
|